Skip to content

Author

P. Svorcan

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access 2026

Safety of adalimumab in inflammatory bowel disease: Insights from a clinical cohort

Real-world data on the safety of adalimumab are essential for ongoing pharmacovigilance, while long-term evidence remains limited. This study aimed to evaluate adverse events (AEs) and their temporal patterns in a cohort of patients with inflammatory bowel disease (IBD). A retrospective observational study included 217...

B. Milašinović, S. Marković, S. Vezmar Kovačević et al. · 0 citations
Open access Sep 2026

Connecting the Dots Between Pharmacokinetics, Inflammatory Biomarkers, and Mucosal Healing in Patients on Infliximab with Inflammatory Bowel Disease

Background/Objectives: Mucosal healing (MH) is a key therapeutic target in inflammatory bowel disease (IBD) associated with sustained remission, reduced hospitalisation, and improved outcomes. Its assessment relies on endoscopic evaluation, which is invasive, costly, and not always feasible. Therapeutic drug monitoring...

A. Homšek Ilić, M. Jovanović, S. Marković et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.